Report
The vaccine patent dilemma
Editorial President Joe Biden this week brought up the issue of temporarily removing patents filed by pharmaceutical companies on COVID-19 vaccines. The European Union and the French president also approved this idea (although nothing has been decided at this stage), while Angela Merkel remained more doubtful. The question is how to identify the cause of the global dose shortfall. Is this due to patents? Insufficient production capacity? Prohibitive costs for the least developed countries? In any case, this debate raises the question of the hierarchy of rights: intellectual property versus public health. The dilemma remains ! For information next Thursday being a holiday, there will be no publication of the Weekly Market next week.
Provider
Natixis
Based across the world’s leading financial centers, Natixis CIB Research offers an integrated view of the markets. The team provides support to inform Natixis clients’ investment and hedging decisions across all asset classes.
Jesus Castillo
Other Reports from Natixis
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.